Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Double-Blind, Placebo-Controlled, Sponsor-Open, Randomized, Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-03654746 in Mild to Moderate Alzheimer's Disease Patients on Stable Donepezil Therapy

NCT01028911 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01028911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01028911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Double-Blind, Placebo-Controlled, Sponsor-Open, Randomized, Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-03654746 in Mild to Moderate Alzheimer's Disease Patients on Stable Donepezil Therapy
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
December 31, 2009
Completion date
May 31, 2010
Enrollment
9 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease